Teleneonatology for Newborn Illness
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how real-time telemedicine consultations with a neonatologist, a doctor specializing in newborn care, can improve the health of at-risk newborns in community hospitals. The study compares two groups: one receiving telemedicine support (referred to as Teleneonatology) and the other following usual care practices without it. Babies born before 32 weeks or needing advanced resuscitation immediately after birth might be suitable for this trial.
As an unphased trial, this study offers a unique opportunity to contribute to innovative care practices for newborns.
Will I have to stop taking my current medications?
The trial information does not specify whether participants need to stop taking their current medications.
What prior data suggests that teleneonatology is safe for newborns?
Research has shown that teleneonatology is generally safe for newborns. Studies have found that this method improves newborn health and reduces the workload for healthcare providers. The studies do not mention specific safety concerns or negative effects related to teleneonatology, suggesting it is well-accepted in practice. Teleneonatology enables specialists to provide expert advice to local hospital teams via video calls, benefiting newborns who need extra care.12345
Why are researchers excited about this trial?
Researchers are excited about teleneonatology because it offers a novel way to provide expert neonatal care remotely. Unlike traditional care where a neonatologist must be physically present, teleneonatology utilizes telemedicine to connect community hospital teams with specialists from regional NICUs. This approach can provide timely, expert consultation to hospitals without immediate access to neonatologists, potentially improving outcomes for newborns in remote or underserved areas.
What evidence suggests that teleneonatology is effective for newborn illness?
Studies have shown that teleneonatology, which uses telemedicine for newborn care, can improve early health outcomes for at-risk babies. Research indicates that it aids in newborn resuscitations and reduces the need to transfer babies to specialized hospitals. In this trial, the Teleneonatology group will receive care from the community hospital team, with telemedicine consultation by a neonatologist from the regional neonatal intensive care unit (NICU). This approach has lowered the number of transfers to NICUs, allowing babies to stay closer to home. These findings suggest that teleneonatology could effectively support newborns needing specialized care in community hospitals.12567
Who Is on the Research Team?
Jennifer Fang, MD
Principal Investigator
Mayo Clinic
Bart Demaerschalk, MD
Principal Investigator
Mayo Clinic
Meegan G Van Straaten, MSPH
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
The TELENEO Trial is for newborns needing advanced resuscitation in community hospitals and the physicians attending these births. Eligible babies may have received ventilation or chest compressions, or be born preterm (<32 weeks). Physicians with neonatal-perinatal specialty are excluded, as are babies planned for comfort care, born outside a birthing center, or with severe congenital anomalies.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Real-time audio-video telemedicine consults with a neonatologist for at-risk neonates in community hospitals
Follow-up
Participants are monitored for early mortality and morbidity outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Teleneonatology
Teleneonatology is already approved in United States, Canada, European Union for the following indications:
- Advanced neonatal resuscitations
- High-risk neonatal care
- Neonatal intensive care
- Remote neonatal consultations
- Neonatal emergency care
- Telemedicine for newborns
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator